Form 4: Cytek Biosciences COO Paul Christopher Williams Reports Stock Transactions

Paul Christopher Williams, COO of Cytek Biosciences, reports the acquisition and disposal of common stock and restricted stock units related to vesting events.

Summary

• On August 19, 2024, Paul Christopher Williams, the Chief Operating Officer of Cytek Biosciences, engaged in multiple transactions involving the company's common stock and restricted stock units (RSUs).
• Williams acquired shares through the vesting of RSUs and simultaneously disposed of shares to cover tax withholding obligations.
• Specifically, Williams acquired 1,006, 920, and 8,840 shares of common stock through RSU vesting.
• Correspondingly, Williams disposed of 392, 359, and 3,444 shares of common stock at a price of $5.53 to satisfy tax obligations.
• Following these transactions, Williams directly owns 16,473 shares of common stock and holds 126,709 restricted stock units.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing detailing stock transactions by a company executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into insider transactions. These filings are common across publicly traded companies and are used to monitor insider activity.

Comparison to Industry Standards

• Executive compensation packages often include restricted stock units that vest over time.
• The vesting schedules described in the document (e.g., quarterly vesting over 4 years) are typical for RSU awards.
• Selling shares to cover tax obligations upon vesting is a standard practice among executives receiving equity compensation.
• Comparable companies such as Becton Dickinson, Thermo Fisher Scientific, and Danaher also have executives who regularly file Form 4s related to stock options and RSU transactions.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
• The filing provides transparency to shareholders regarding insider transactions.

Key Dates